Dr Reddy's Laboratories sees generic Revlimid, other launches to keep US business firing

The Hyderabad-based drug maker on Friday reported its highest ever revenues, largely driven by generic Revlimid launch during the second quarter of FY23, and partly due to favorable movement of forex rates and rebound of Russia business.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/T8zfo4d
via IFTTT